Ribozymes as tools for therapeutic target validation in arthritis

Journal of Immunology

Volumn 165, Issue 1, 2000, Pages 493-498

  Jarvis, Thale C ^a,d   Bouhana, Karyn S ^b   Lesch, Mark E ^c   Brown, Suzy A ^d   Parry, Tom J ^b   Schrier, Denis J ^c   Hunt III, Stephen W ^c   Pavco, Pamela A ^b   Flory, Craig M ^c  

^a Impact Biosciences   (United States)

^b Sirna Therapeutics Inc   (United States)

^c PFIZER INC   (United States)

^d Atugen USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBOZYME;

ARTHRITIS; ARTICLE; CARTILAGE DEGENERATION; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOTHERAPY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING;

EID: 0034234597     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.1.493     Document Type: Article

References (25)

1. Brinckerhoff, C. 1991. Joint destruction in arthritis: metalloproteinases in the spotlight. Arthritis Rheum. 34:1073.
2. Hembry, R., Bagga, M., Reynolds, J., and Hamblen, D. 1995. Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis. Annu. Rheum. Dis. 54: 25.
3. Okada, Y., Shinmei, M., Tanaka, O., Naka, K., Kimura, A., Nakanishi, I., Bayliss, M., Iwata, K., and Nagase, H. 1992. Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium. Lab. Invest. 66:680.
4. Hasty, K., Reife, R., Kang, A., and Stuart, J. 1990. The role of stromelysin in the cartilage destruction that accompanies inflammatory arthritis. Arthritis Rheum. 33:388.
5. Cech, T. R. 1992. Ribozyme engineering. Curr. Opin. Struct. Biol. 2:605.
6. Zaug, A., Been, M., and Cech, T. 1986. The Tetrahymena ribozyme acts like an RNA restriction endonuclease. Nature 324:429.
7. Breaker, R. 1997. In vitro selection of catalytic polynucleotides. Chem. Rev. 97:371.
8. Uhlenbeck, O. 1987. A small catalytic oligoribonucleotide. Nature 328:596.
9. Lange, W., E. M. Cantin, J. Finke, and G. Dolken. 1993. In vitro and in vivo effects of synthetic ribozymes targeted against bcr/abl mRNA. Leukemia 7:1786.
10. Jarvis, T., L. Alby, A. Beaudry, F. Wincott, L. Beigelman, J. McSwiggen, N. Usman, and D. Stinchcomb. 1996. Inhibition of vascular smooth muscle cell proliferation by ribozymes that cleave c-myb mRNA. RNA 2:419.
11. Sioud, M. 1994. Interaction between tumour necrosis factor a ribozyme and cellular proteins. J. Mol. Biol. 242:619.
12. Snyder, D. S., Y. Wu, J. L. Wang, J. J. Rossi, P. Swiderski, B. E. Kaplan, and S. J. Forman. 1993. Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood 82:600.
13. Beigelman, L., J. McSwiggen, K. Draper, C. Gonzalez, K. Jensen, A. Karpeisky, A. Modak, J. Matulic-Adamic, A. DiRenzo, P. Haeberli, et al. 1995. Chemical modification of ribozymes: catalytic activity and nuclease resistance. J. Biol. Chem. 270:25702.
14. Flory, C., P. Pavco, T. Jarvis, M. Lesch, F. Wincott, L. Beigelman, S. Hunt, and D. Schrier. 1996. Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint. Proc. Natl. Acad. Sci. USA 93:754.
15. Lyngstadaas, S. P., S. Risnes, B. S. Sproat, P. S. Thrane, and H. P. Prydz. 1995. A synthetic, chemically modified ribozyme eliminates amelogenin, the major translation product in developing mouse enamel in vivo. EMBO J. 14:5224.
16. Wincott, F., A. DiRenzo, C. Shaffer, S. Grimm, D. Tracz, C. Workman, D. Sweedler, C. Gonzalez, S. Scaringe, and N. Usman. 1995. Synthesis, deprotection, analysis and purification of RNA and ribozymes. Nucleic Acids Res. 23:2677.
17. Farndale, R., C. Sayers, and A. Barrett. 1982. A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connect. Tissue Res. 9:247.
18. Christoffersen, R. E., J. McSwiggen, and D. Konings. 1994. Application of computational technologies to ribozyme biotechnology products. J. Mol. Struct. (Theochem) 311:273.
19. Hutchinson, N., M. Lark, K. MacNaul, C. Harper, L. Hoerrner, J. McDonnell, S. Donatelli, V. Moore, and E. Bayne. 1992. In vivo expression of stromelysin in synovium and cartilage of rabbits injected intraaarticularly with interleukin-1β. Arthritis Rheum. 35:1227.
20. Wojtowicz-Praga, S., J. Low, J. Marshall, E. Ness, R. Dickson, J. Barter, M. Sale, P. McCann, J. Moore, A. Cole, and M. Hawkins. 1996. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest. New Drugs 14:193.
21. Mudgett, J., N. Hutchinson, N. A. Chartrain, A. Forsyth, J. McDonnell, I. Singer, E. Bayne, J. Flanagan, D. Kawka, C. Shen, et al. 1998. Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction. Arthritis Rheum. 41:110.
22. Lohmander, L. 1994. Articular cartilage and osteoarthrosis: the role of molecular markers to monitor breakdown, repair and disease. J. Anat. 184:477.
23. MacPherson, L., E. Bayburt, M. Capparelli, B. Carroll, R. Goldstein, M. Justice, L. Zhu, S. Hu, R. Melton, L. Fryer, et al. 1997. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J. Med. Chem. 40:2525.
24. Parry, T. J., C. Cushman, A. M. Gallego, A. B. Agrawal, M. Richardson, L. E. Andrews, L. Maloney, V. R. Mokler, F. E. Wincott, and P. A. Pavco. 1999. Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA. Nucleic Acids Res. 27:2569.
25. Pavco, P. A., K. S. Bouhana, A. M. Gallegos, A. Agrawal, K. S. Blanchard, S. L. Grimm, K. L. Jensen, L. E. Andrews, F. E. Wincott, P. A. Pilot, R. J. Tressler, C. Cushman, M. A. Reynolds and T. J. Parry. 2000. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin. Cancer Res. 6:2094.